LPCN Chart
- 52-Week Range: $0.73 - $1.85
- Market Capitalization: $82.05M
- Short Percentage: 0%
- Target Price: $3.63
- Shares Outstanding: 88.50M
- Next Earnings: Nov 30
Catalysts
CategoryCatalyst
Earnings
LPCN released their earnings report for the previous quarter and provided guidance on the current and upcoming quarters.
News and Press Releases
- Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO®PRNewsWire | January 27th
- Lipocine Is One To Watch Based On Possible FDA Approval Of TLANDO And NASH DataSeeking Alpha | November 11th
- Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2021PRNewsWire | November 10th
- Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In USBenzinga | October 18th
- Lipocine And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO®PRNewsWire | October 18th
- Lipocine to Present at The H.C. Wainwright 5th Annual NASH Investor ConferencePRNewsWire | October 5th
- Lipocine Announces FDA Affirmation Of Class 1 NDA Resubmission For TLANDO®PRNewsWire | September 28th
- Lipocine to Present at The Cantor Fitzgerald Virtual Global Healthcare ConferencePRNewsWire | September 20th
- Lipocine to Present at The H.C. Wainwright 23rd Annual Global Investment ConferencePRNewsWire | September 1st
Company Info
Website: https://www.lipocine.com
Address: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108
Sector: Healthcare
Industry: Biotechnology
Full time employees: 13
Address: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108
Sector: Healthcare
Industry: Biotechnology
Full time employees: 13
$LPCN buy
$LPCN Yolo
$LPCN ADDING MORE…
$LPCN bag holders for life club
$LPCN Games being played here.
$LPCN more shorts the better idc
$LPCN buying puts